Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view

References

• Barrios V, Calderón A, Escobar C, de la Figuera M. Primary Care Group in the Clinical Cardiology Section of the Spanish Society of Cardiology. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol 2012;65(1):47-53
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983-8
   PubMed Web of Science ®Google Scholar
• Masjuán J, Álvarez-Sabín J, Blanco M, et al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack. Rev Neurol 2014;59(1):25-36
   PubMed Web of Science ®Google Scholar
• Schwammenthal Y, Bornstein N, Schwammenthal E, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol 2010;105(3):411-16
   Google Scholar
• Planas F, Antunez F, Poblet T, et al. Clinical profile of idiopathic paroxysmal atrial fibrillation (FAP registry). Rev Esp Cardiol 2011;54(7):838-44
   Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370-5
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Esp Cardiol 2014;67(2):150-1
   PubMed Web of Science ®Google Scholar
• Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010;104(3):642-9
   PubMed Web of Science ®Google Scholar
• Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2013;95(19):1801-11
   PubMedGoogle Scholar
• Bang SM, Jang MJ, Kim KH, et al. Korean Society of Thrombosis and Hemostasis. Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci 2014;29(2):164-71
   Google Scholar
• Guyatt GH, Akl EA, Crowther M, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S
   Google Scholar
• Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379(9828):1835-46
   PubMed Web of Science ®Google Scholar
• Hutten BA, Prins MH, Hutten BA. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2014;8:CD001367
   Google Scholar
• Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179(5):417-26
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e419S-94S
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52
   PubMed Web of Science ®Google Scholar
• EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
   PubMed Web of Science ®Google Scholar
• EINSTEIN-PE Investigators. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366(14):1287-97
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799-808
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther 2013;11(2):129-41
   PubMedGoogle Scholar
• Barrios V, Escobar C. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Expert Opin Pharmacother 2012;13(18):2649-61
   PubMed Web of Science ®Google Scholar
• Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009(124(1):37-41
   Google Scholar
• Barrios V, Escobar C, Polo J, et al. Current status of anticoagulation in primary care. Preliminary data of the PAULA study. Rev Esp Cardiol 2014;67(Supl 1):6050-643
   Google Scholar
• Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15(3):244-52
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Roldan C. Anticoagulation in non-valvular atrial fibrillation: underused or wrongly used? Am J Cardiol 2011;108(11):1687-8
   PubMed Web of Science ®Google Scholar
• Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014;74(11):1209-31
   PubMed Web of Science ®Google Scholar
• Partida RA, Giugliano RP. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiol 2011;7(4):459-70
   PubMedGoogle Scholar
• Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50(7):743-53
   PubMed Web of Science ®Google Scholar
• Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol 2014;70(11):1339-51
   PubMed Web of Science ®Google Scholar
• Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011;51(5):687-94
   PubMed Web of Science ®Google Scholar
• Savaysa® Brief Summary of prescribing information. Available from: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa%20Med&inline=true
   Google Scholar
• Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007;98(4):883-8
   PubMed Web of Science ®Google Scholar
• No authors listed Edoxaban tosylate. Am J Cardiovasc Drugs 2011;11(2):129-35
   Google Scholar
• Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104(3):633-41
   PubMed Web of Science ®Google Scholar
• Song S, Kang D, Halim AB, Miller R. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment. J Clin Pharmacol 2014;54(8):910-16
   PubMed Web of Science ®Google Scholar
• Renda G, De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013;59(3-4):53-62
   Google Scholar
• Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition. Drug Metab Dispos 2014;42(4):520-8
   PubMed Web of Science ®Google Scholar
• Plitt A, Giugliano RP. Edoxaban: Review of pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther 2014;19(5):409-16
   PubMed Web of Science ®Google Scholar
• Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13(5):331-42
   PubMed Web of Science ®Google Scholar
• Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol 2012;60(4):335-41
   PubMed Web of Science ®Google Scholar
• Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012;107(5):925-36
   PubMed Web of Science ®Google Scholar
• Mendell J, Lee F, Chen S, et al. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol 2013;62(2):212-21
   PubMed Web of Science ®Google Scholar
• Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011;105(3):535-44
   PubMed Web of Science ®Google Scholar
• Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with nonvalvular atrial fibrillation. Circ J 2012;76(8):1840-7
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160(4):635-41
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365(11):981-92
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Rost NS, et al. ENGAGE AF-TIMI 48 Investigators. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke 2014;45(8):2372-8
   PubMed Web of Science ®Google Scholar
• Rost NS, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban vs. warfarin in high-risk patients: the ENGAGE AF-TIMI 48 trial. Presented at 9TH World Stroke Congress 22-25 October. Istanbul. Turkey. Abstract WSC-1119 2014
   Google Scholar
• Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48. Circulation 2014;130:A16612
   Web of Science ®Google Scholar
• Xu H, Ruff CT, Giugliano RP, et al. Concomitant use of antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Circulation;2014;130:A19119
   Google Scholar
• O’Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J 2015. [Epub ahead of print]
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; Epub ahead of print
   Google Scholar
• Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; Epub ahead of print
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2014;64(6):576-84
   PubMed Web of Science ®Google Scholar
• Bauersachs R. Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. Clin Invest 2014;4:619-39
   Google Scholar
• Raskob G, Buller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. J. Thromb Haemost 2013;11(7):1287-94
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE Investigators. Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406-15
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129(7):764-72
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368(8):709-18
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708
   PubMed Web of Science ®Google Scholar
• Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010;8(11):2458-68
   PubMed Web of Science ®Google Scholar
• Fuji T, Wang C-J, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplast 2014;29(12):2439-46
   PubMed Web of Science ®Google Scholar
• Fuji T, Wang CJ, Fujita S, et al. Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial. Thromb Res 2014;134(6):1198-204
   PubMed Web of Science ®Google Scholar
• Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial [abstract]. 52nd American Society of Hematology (ASH) Annual Meeting 2010. p-3320
   Google Scholar
• Fuji T, Fujita S, Kawai Y, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res 2014;133(6):1016-22
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Hirayama C, Hotoda H, et al. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vas Health Risk Manag 2013;9:593-8
   PubMedGoogle Scholar
• Sasaki H, Ishida K, Shibanuma N, et al. Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty. Int Orthop 2014;38(3):525-9
   Google Scholar
• Food and Drug Administration. FDA approves anticlotting drug Savaysa [press release]. January 8. Available from: www.fda.gov/newsevents/newsroom/pressannouncements/ucm429523.htm 2015
   Google Scholar
• Summary of opinion (initial authorization). Lixiana (edoxaban). 2015. Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002629/WC500186182.pdf [Last Accessed on 23 April 2015]
   Google Scholar
• Lixiana® (edoxaban). Prescribing Information. Daiichi Sankyo (Switzerland) AG. 2015
   Google Scholar
• Edoxaban for TIA and Acute Minor Stroke. Available from: https://clinicaltrials.gov/ct2/show/NCT02221102
   Google Scholar
• Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF). Available from: https://clinicaltrials.gov/ct2/show/NCT02072434
   Google Scholar
• Edoxaban in Peripheral Arterial Disease (ePAD). Available from: https://clinicaltrials.gov/ct2/show/NCT01802775
   Google Scholar
• Phase 1 Pediatric PK/PD Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02303431
   Google Scholar
• Cancer Venous Thromboembolism (VTE). Available from: https://clinicaltrials.gov/ct2/show/NCT02073682
   Google Scholar
• Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation (AFTER-CV). Available from: https://clinicaltrials.gov/ct2/show/NCT01924065
   Google Scholar
• START-Register: Survey on Anticoagulated Patients Register. Available from: https://clinicaltrials.gov/ct2/show/NCT02219984
   Google Scholar
• Register for New Oral Anticoagulants (NOAC). Available from: https://clinicaltrials.gov/ct2/show/NCT01588119
   Google Scholar
• Renda G, De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013;59(3-4):53-62
   Google Scholar
• Laliberté F, Nelson WW, Lefebvre P, et al. Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients. Adv Ther 2012;29(8):675-90
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33(21):2719-47
   PubMed Web of Science ®Google Scholar
• Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19(4):446-51
   PubMed Web of Science ®Google Scholar
• Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012;107(2):253-9
   PubMed Web of Science ®Google Scholar
• Herzog E, Kaspereit F, Krege W, et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology 2015;122(2):387-98
   PubMed Web of Science ®Google Scholar
• Zahir H, Brown KS, Vandell A, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015;131(1):82-90
   PubMed Web of Science ®Google Scholar
• Vanden Daelen S, Peetermans M, Vanassche T, et al. Monitoring and reversal strategies for new oral anticoagulants Expert Rev Cardiovasc Ther 2015;13(1):95-103
   Google Scholar
• Mark C, Vandana M, Michael K, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors [abstract]. 55th American Society of Hematology (ASH) Annual Meeting 2013. p. 3636
   Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014;371(22):2141-2
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, Liberato NL. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis 2015;39(2):149-54
   PubMed Web of Science ®Google Scholar
• Krejczy M, Harenberg J, Wehling M, et al. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. Biomed Res Int 2015;2015:876923
   PubMed Web of Science ®Google Scholar
• Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics 2015;33(4):395-408
   Google Scholar